Select Page

On Friday, Vyant Bio, the biotech company that saw its shares delisted from Nasdaq in May, revealed its projections for liquidation payments to shareholders. The anticipated range per share is between $0.16 and $0.29. Since its delisting, Vyant has been trading over-the-counter (OTC) and completed the sale of the majority of its assets in October. Looking ahead, the company disclosed its plans to file a Certificate of Dissolution in late December 2023, with expectations to initiate the first round of liquidation payments in the fourth quarter of 2024. Vyant Bio continues to navigate its financial course, providing clarity to its investors amidst these significant corporate developments.